C92.32
Myeloid sarcoma, in relapse
Clinical Classification Guidelines
Medical Intelligence & Overview
Myeloid sarcoma, also known as granulocytic sarcoma or chloroma, is a rare type of cancer that involves the abnormal growth of myeloid cells outside the bone marrow. When it occurs in relapse, it indicates that the disease has returned after previous treatment. This condition is associated with acute myeloid leukemia (AML) and can affect various tissues or organs throughout the body. Recognizing the signs and understanding the nature of myeloid sarcoma in relapse is important for managing the disease effectively, often involving a multidisciplinary medical approach.
Causes & Symptoms
Clinical Causes: Relapse of underlying acute myeloid leukemia (AML) Genetic mutations leading to abnormal myeloid cell proliferation Previous treatment failure or incomplete remission Presence of residual cancer cells that proliferate after therapy Potential environmental or genetic predispositions influencing disease recurrence
Key Symptoms: Localized swelling or mass, often in skin, lymph nodes, or soft tissues Pain or discomfort at the site of tumor growth Unexplained weight loss Fever or night sweats Fatigue and weakness Signs related to organ involvement, such as breathing difficulty if lungs are affected Additional symptoms may vary depending on the specific tissues or organs involved
Diagnostic & Treatment
Diagnosis Path: Diagnosis of myeloid sarcoma in relapse typically involves a combination of medical history, physical examination, and several laboratory and imaging tests. These may include:
Treatment Protocols: Managing myeloid sarcoma in relapse generally requires an aggressive and tailored approach, often involving therapies similar to those used in AML treatment. Common strategies include:
Clinical Advice & FAQs
Billing Guidance
Is C92.32 a billable ICD-10 code?
Yes, C92.32 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C92.32?
Clinical documentation must specify the nature of Myeloid sarcoma, in relapse and any associated comorbidities for accurate reporting.
Cite this Clinical Reference